ZMapp

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Ebola VirusHealthy

Phase 1

Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers

WithdrawnNCT02389192

National Institute of Allergy and Infectious Diseases (NIAID)Healthy

Start: 2015-03-11End: 2017-12-27Updated: 2019-12-16

Phase 2

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

CompletedNCT03719586

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Virus

Start: 2018-11-21End: 2020-08-18Updated: 2021-09-08

Related Papers

Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series.

2020-12-018 citations

Antibodies to watch in 2020.

2020-01-01328 citations

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

New England Journal of Medicine2019-11-271573 citations